Universitetshospital, Odense, Denmark; 9 Odense University Hospital, Odense, Denmark BACKGROUND The risk of developing late acquired stent malap- position (LASM) after drug-eluting stent (DES) implantation in the clinical setting of a ST-segment Elevation Myocardial Infarction (STEMI) is high due to dissolution of initially jailed thrombus. LASM is a potential risk factor in the subsequent development of later major adverse cardiac events (MACE). The 5-year clinical impact of intra- vascular ultrasound (IVUS) detected 12-month LASM in STEMI-pa- tients treated with primary percutaneous coronary intervention and implantation of Biolimus-eluting Nobori (BES) (Terumo, Tokyo, Japan) and Sirolimus-eluting Cypher (SES) (Cordis, Johnson & John- son, New Jersey, USA) stents was assessed. METHODS In the Randomized Comparison of Biolimus-Eluting Biodegradable Polymer Coated Stent and Durable Polymer Sirolimus- Eluting Stent in Unselected Patients (SORT OUT V) trial, a prespecified IVUS substudy enrolled 116 STEMI-patients (57 BESs and 59 SESs) where post-procedure and 12-month follow-up IVUS-data were available. LASM was defined as stent malapposition not present post- procedure but at 12-month follow-up. The possible correlation be- tween IVUS-detected 12-month LASM and 5-year MACE (composite endpoint of myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), all-cause mortality, car- diac death and very late stent thrombosis (VLST)) was evaluated. RESULTS The 5-year MACE rate did not differ between the LASM- group (19 patients) versus the non-LASM-group (97 patients); 10.5% vs. 12.4%, p¼0.59. Neither, were there any differences when evalu- ating the occurrence of the 5-year prevalence of MI: 10.5% vs. 7.2%, p¼0.45; TLR: 10.5% vs. 6.2%, p¼0.39; TVR: 15.8% vs. 10.3%, p¼0.36; all-cause mortality: 0.0% vs. 5.2%, p¼0.40; cardiac death: 0.0% vs. 1.0%, p¼0.84, and VLST: 5.3% vs. 1.0%, p¼0.30, respectively, in the LASM-group vs. the non-LASM-group. CONCLUSION The presence of 12-month LASM did not influence on the 5-year MACE rate. Other arterial healing factors such as hetero- geneous coverage, chronic inflammation and hypersensitivity re- actions might play important co-predisposing roles in DES-treated STEMI-patients who subsequently suffer from MACE. CATEGORIES IMAGING: Intravascular TCT-552 SERIAL ASSESSMENT OF CALCIFICATION 5 YEARS AFTER BIORESORBABLE VASCULAR SCAFFOLD IMPLANTATION: FUSION OF INTRAVASCULAR ULTRASOUND AND OPTICAL COHERENCE TOMOGRAPHY Yaping Zeng, 1 Hiroki Tateishi, 2 Rafael Cavalcante, 3 Erhan Tenekecioglu, 4 pannipa suwannasom, 5 Yohei Sotomi, 6 Carlos Collet, 7 Shao-Ping Nie, 8 Hans Jonker, 9 Jouke Dijkstra, 10 Maria Radu, 11 Lorenz Raber, 12 Dougal Mcclean, 13 Robert-Jan van Geuns, 14 Evald Christiansen, 15 Fahrni Therese, 16 Jacques Koolen, 17 Yoshinobu Onuma, 18 Patrick Serruys 19 1 Centro Cardiologico Monzino, Rotterdam, Netherlands; 2 Erasmus MC, Rotterdam, Netherlands; 3 Thoraxcenter, Erasmus MC, Rotterdam, Netherlands; 4 Erasmus MC, Rotterdam, Netherlands; 5 Erasmus MC, rotterdam, Netherlands; 6 EMC, Rotterdam, Netherlands; 7 Clinica El Avila, Caracas, Venezuela; 8 Beijing Anzhen Hospital, Beijing, Beijing, China; 9 EVMS; 10 Medis Medical Imaging Systems, Inc., Raleigh, North Carolina, United States; 11 The Heart Centre, Rigshospitalet, Copenhagen, Denmark; 12 University Hospital Bern, Bern, Switzerland; 13 Christchurch Hospital, Christchurch, New Zealand; 14 Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands; 15 Aarhus University Hospital, Aarhus, Denmark; 16 Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan; 17 catharina hospital eindhoven netherlands; 18 Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands; 19 Imperial College, London/Thoraxcenter of Erasmus University, Rotterdam, Netherlands BACKGROUND Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) have individual strengths in assessing plaque composition and volume. METHODS Anatomic landmarks and endoluminal radiopaque markers were used to fuse OCT and IVUS images and match baseline and follow-up. RESULTS 72 cross sections (CS) with 4 imaging modalities (OCT, GS- IVUS, VH-IVUS, echogenicity) in- and out-scaffold segments were fused at baseline and at 5 years follow-up (total number of CS¼576). In total, 46 calcified plaques at follow-up were detected by the fusion method (33 in-, 13 out-scaffold), showing either calcium progression (52.2%) or de novo calcifications (47.8%). On OCT, calcification vol- ume increased from baseline to follow-up by 2.3Æ2.4 mm3 (p¼0.001). Minimal intima thickness overlying calcium increased significantly more in-scaffold (D:180mmÆ152mm) than out-scaffold segments (D:16mmÆ116mm) (p¼0.034, in-vs out-scaffold). The baseline VH tissue precursors of dense calcium (DC) at follow-up were necrotic core (NC) in 73.9% and Fibrous/Fibrofatty (F/FF) in 10.9%. In 15.2%, calcium was already present at baseline. Precursors on OCT were lipid pool in 71.2%, fibrous in 4.3%, and fibrocalcific plaque in 23.9%. CONCLUSION The use of OCT/IVUS fusion imaging shows similar calcium growth in-and out-scaffold segments. NC is the most frequent precursor of calcification. The scaffold resorption process creates a tissue layer that recaps the calcified plaques. CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds TCT-553 An Optical Coherence Tomography Comparison of Coronary Arterial Plaque Calcification in a Matched Cohort of Patients With and Without End-Stage Renal Disease and Diabetes Mellitus Joseph Weber, 1 Nicholas Kassis, 2 Kunal Shah, 3 John Lopez 4 1 Wroclaw Medical University, Military Hospital, Wroclaw, Poland, Villa Park, Illinois, United States; 2 Loyola University Chicago; 3 Ota Memorial Hospital; 4 lumc, Chicago, Illinois, United States BACKGROUND Coronary arterial plaques in patients (pts) with end- stage renal disease (ESRD) are assumed to have increased calcification due to ESRD or initiation of dialysis. This relationship may be confounded by comorbidities, including diabetes mellitus (DM), a cause of calcific atherosclerosis. METHODS From a single-center OCT registry, 45 pts were analyzed: 15 pts with ESRD were matched 1:1 for age (Æ 10 yrs) and gender to 2 cohorts of non-ESRD pts: 15 pts with DM and 15 without DM (non-DM). ESRD was defined as an eGFR of <15 or need for kidney replacement therapy. One lesion per pt was analyzed in the culprit vessel defined as a 10mm segment centered on the minimal lumen area slice. Lesions were analyzed at 1mm intervals by 2 experienced readers. Lesion calcium (Ca) burden was deter- mined by summing Ca at 1mm intervals, and mean Ca arc, distance of Ca from the lumen (location), and number of deposits were also compared. Continuous variables are expressed as mean Æ standard deviation. Data were analyzed using a Wilcoxon Signed-Rank Test. RESULTS Groups were similar in age (ESRD 60.3Æ7.5; DM 63.8Æ7.3; Non-DM 62.6Æ8.0) and gender. 4(27%) ESRD pts were on peritoneal dialysis, 10(67%) were on hemodialysis, and 1(7%) received both. Mean dialysis duration was 1.8Æ1.9 yrs. Dialysis duration did not correlate with lesion Ca burden (r¼0.001, p¼ns). See table for analysis of calcification measures. Variable ESRD (n [ 15) DM (n [ 15) Non-DM (n [ 15) p Value ESRD vs. Non- DM DM vs. Non- DM Calcium arc 50.6 Æ 17.1 45.6 Æ 21.6 22.5 Æ 25.4 <0.05 <0.05 Calcium area sum (mm2) 11.7 Æ 8.7 11.5 Æ 11.9 5.0 Æ 8.1 0.05 <0.05 Calcium location (mm) 0.1 Æ 0.1 0.1 Æ 0.1 0.1 Æ 0.1 0.06 <0.05 Number of calcium deposits 20.3 Æ 10.4 17.5 Æ 10.6 5.8 Æ 8.7 <0.05 <0.05 CONCLUSION No significant differences in any measure of lesion calcification were identified between ESRD and DM pts. When ESRD and DM pts were compared to Non-DM pts, significant differences were seen in Ca arc, area, and number of Ca deposits. Despite the assump- tion that ESRD or dialysis is responsible for increased coronary plaque calcification, enhanced lesion calcification in ESRD may instead be related to advanced atherosclerosis and confounded by DM. CATEGORIES CORONARY: Diabetes TCT-554 Meta-analysis of randomized trials evaluating the outcomes with intravascular ultrasound guided stent implantation Islam Elgendy, 1 Ahmed Mahmoud, 2 Akram elgendy, 3 Anthony Bavry 4 1 University of Florida, Gainesville, Florida, United States; 2 University of Florida, Gainesville, Florida, United States; 3 University of Florida; 4 University of Florida Health, Gainesville, Florida, United States JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, VOL. 68, NO. 18, SUPPL B, 2016 B223